118156-93-7

Basic information

• Product Name: 1-BOC-3-PIPERIDINECARBOXALDEHYDE
• Synonyms: N-BOC-3-PIPERIDINYLCARBOXALDEHYDE;N-BOC-3-FORMYLPIPERIDINE;BOC-3-PIPERIDINECARBOXALDEHYDE;BUTTPARK 147\06-01;1-BOC-3-PIPERIDINECARBOXALDEHYDE;1-N-BOC-3-FORMYLPIPERIDINE;3-FORMYLPIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-Boc-3-formylpiperidine
• CAS NO: 118156-93-7
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27
• Product Categories: pharmacetical;Piperidine
• Mol File: 118156-93-7.mol

Chemical Properties

• Boiling Point: 295.4 °C at 760 mmHg
• Flash Point: 132.5 °C
• Appearance: /
• Density: 1.114 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -2.29±0.40(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 1-BOC-3-PIPERIDINECARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3-PIPERIDINECARBOXALDEHYDE(118156-93-7)
• EPA Substance Registry System: 1-BOC-3-PIPERIDINECARBOXALDEHYDE(118156-93-7)

Safety Data

• Hazard Codes: Xi,N,Xn
• Statements: 36/37/38-50-36-22
• Safety Statements: 26-36/37/39-61-37
• RIDADR: UN3077
• Hazardous Substances Data: 118156-93-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-3-PIPERIDINECARBOXALDEHYDE is used as an organic chemical synthesis intermediate for the development of new pharmaceutical compounds. Its unique structure allows for the creation of a wide range of drugs with potential therapeutic applications, including those targeting central nervous system disorders, pain management, and other medical conditions.
Used in Chemical Industry:
1-BOC-3-PIPERIDINECARBOXALDEHYDE is also utilized as a key intermediate in the synthesis of various chemicals, such as agrochemicals, dyes, and other specialty chemicals. Its versatility in chemical reactions enables the production of a diverse array of products with specific properties and applications in different sectors.

InChI:InChI=1/C11H19NO3/c1-11(2,3)15-10(14)12-6-4-5-9(7-12)8-13/h8-9H,4-7H2,1-3H3

Upstream product

• 79-37-8 oxalyl dichloride 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 7529-22-8 4-methylmorpholine N-oxide 
• 4606-65-9 3-(hydroxymethy)piperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 114615-82-6 tetrapropylammonium perruthennate 
• 498-95-3 nipecotic acid 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 189442-78-2 (±)-tert-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 

Downstream Products

• 78190-11-1 1-benzyloxycarbonylpiperidine-3-carboxylic acid 
• 406212-87-1 tert-butyl 2-amino-6-[2,6-bis(benzyloxy)phenyl]-4-[1-(tert-butoxycarbonyl)-3-piperidinyl]nicotinate 
• 1029526-16-6 tert-butyl 3-(6-(6-(4-fluorophenyl)imidazo[2,1-b]oxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)piperidine-1-carboxylate 
• 189442-04-4 3-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 
• 858644-30-1 tert-butyl 3-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]piperidine-1-carboxylate 
• 664362-16-7 tert-butyl 3-ethynylpiperidine-1-carboxylate 
• 896053-81-9 4-Benzyl-1-piperidin-3-ylmethyl-piperidine 
• 744216-08-8 6'-(2-benzyloxy-phenyl)-3'-cyano-2'-diacetylamino-3,4,5,6-tetrahydro-2H-[3,4']bipyridinyl-1-carboxylic acid tert-butyl ester 
• 406212-69-9 tert-butyl 3-{2-(acetylamino)-6-[2-(benzyloxy)phenyl]-3-cyano-4-pyridinyl}-1-piperidinecarboxylate 

Relevant articles and documents

(E) and (Z)-3-styrylpiperidines as sigma ligands

A class of (E) and Q-3-styrylpiperidine derivatives was prepared as racemates and evaluated for affinity at σ binding sites labeled with [3H]-(±-SKF-10,047. Some of these compounds exhibited high affinity and selectivity for σ verus D1 and D2 binding sites.

NOVEL HISTONE METHYLTRANSFERASE INHIBITORS

The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.

Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia

BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively. 3a-P1 displayed a good safety profile in a battery of assays, including single-dose toxicity, hERG K+, and genotoxicity. It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL). Importantly, 3a-P1 demonstrated a higher potency than ponatinib in a mice xenograft model of BaF3 harboring BCR-ABLT315I. Overall, the results indicate that 3a-P1 is a promising drug candidate for the treatment of CML to overcome the imatinib-resistant T315I BCR-ABL mutation.

Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B

The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymatic activity with cardiovascular, neurological, and oncological disorders. This has promoted increased research into selective MAO-A and MAO-B inhibitors. Here, we shed light on how selective inhibition of MAO-A and MAO-B can be achieved by geometric isomers of cis-and trans-1-propargyl-4-styrylpiperidines. While the cis isomers are potent human MAO-A inhibitors, the trans analogues selectively target only the MAO-B isoform. The inhibition was studied by kinetic analysis, UV-vis spectrum measurements, and X-ray crystallography. The selective inhibition of the MAO-A and MAO-B isoforms was confirmed ex vivo in mouse brain homogenates, and additional in vivo studies in mice show the therapeutic potential of 1-propargyl-4-styrylpiperidines for central nervous system disorders. This study represents a unique case of stereoselective activity of cis/trans isomers that can discriminate between structurally related enzyme isoforms.

A kind of protease inhibitor and its preparation and use

The invention discloses a kind of protease inhibitors, and preparation method and application thereof. The invention discloses a kind of compounds and pharmaceutical compositions thereof, and a preparation method and application thereof. The invention relates to a kind of compounds capable of reducing or inhibiting activity of dual leucine zipper kinase in cells or a subject, and application of the compounds, or solvates, hydrates or medicinal salts thereof to prevent or treat patient diseases or related diseases caused by abnormity of dual leucine zipper kinase.

A kind of to reduce the intraocular pressure of the compound and its preparation and use

The invention discloses a kind of compounds reducing intraocular pressure, and a preparation method and application thereof. The application is application to prepare medicines for reducing intraocular pressure. The above compounds have extremely substantial effect on reducing intraocular pressure.

BTK INHIBITOR

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)

Protein Kinase Inhibitors

The present invention relates to compounds of Formula I: as well as pharmaceutically acceptable salts, hydrates, isomers, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula I, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.

Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs

Here we report the discovery and early SAR of a series of mGluR5 negative allosteric modulators (NAMs). Starting from a moderately active HTS hit we synthesized 3,5-disubstituted-oxadiazoles and tetrazoles as mGluR5 NAMs. Based on the analysis of ligand e